Author

Lorna Charles

PREGNANCY OUTCOMES IN THE OZANIMOD CLINICAL DEVELOPMENT PROGRAM IN ULCERATIVE COLITIS, CROHN’S DISEASE, AND RELAPSING MULTIPLE SCLEROSIS
PREGNANCY OUTCOMES IN THE OZANIMOD CLINICAL DEVELOPMENT PROGRAM IN ULCERATIVE COLITIS, CROHN’S DISEASE, AND RELAPSING MULTIPLE SCLEROSIS

Lorna Charles  et al.

SAFETY OF CONCURRENT ADMINISTRATION OF OZANIMOD AND SEROTONERGIC ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS
SAFETY OF CONCURRENT ADMINISTRATION OF OZANIMOD AND SEROTONERGIC ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS

Lorna Charles  et al.

LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS) STUDIES
LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS) STUDIES

Lorna Charles  et al.

LONG-TERM SAFETY OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS
LONG-TERM SAFETY OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS

Lorna Charles  et al.

HEPATIC SAFETY OF OZANIMOD IN ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS PHASE 3 TRIALS
HEPATIC SAFETY OF OZANIMOD IN ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS PHASE 3 TRIALS

Lorna Charles  et al.

LONG-TERM SAFETY AND EFFICACY OF OZANIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE TOUCHSTONE OPEN-LABEL EXTENSION
LONG-TERM SAFETY AND EFFICACY OF OZANIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE TOUCHSTONE OPEN-LABEL EXTENSION

Lorna Charles  et al.

EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL
EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL

Lorna Charles  et al.

OZANIMOD AS INDUCTION THERAPY IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY
OZANIMOD AS INDUCTION THERAPY IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Lorna Charles  et al.

OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY
OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Lorna Charles  et al.

Item 1 - 9 / 9
1